Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01770379 · ClinicalTrials.gov registry record · Phase 3
Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 242
- Enrollment target
NCT01770379 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 242 participants.
The verdict
NCT01770379, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 242 participants
- Enrollment target
Study Summary
This study will provide efficacy and safety data of the secukinumab pre-filled syringe (PFS) for subcutaneous self-administration in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α agents.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Secukinumab (AIN457)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01770379
The ClinicalTrials.gov registry entry for NCT01770379 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01770379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01770379 about?
NCT01770379 is a clinical study titled "Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.". This study will provide efficacy and safety data of the secukinumab pre-filled syringe (PFS) for subcutaneous self-administration in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α agents.
What is the current status of trial NCT01770379?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2012-10. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01770379?
The interventions under investigation include: Placebo (BIOLOGICAL), Secukinumab (AIN457) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01770379?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.